Judy Lieberman

Apr 10, 2024 | nature.com | Gang Du |Liam Healy |Liron David |Caitlin Walker |Tarick J. El-Baba |Corinne A. Lutomski | +12 more

AbstractGasdermin D (GSDMD) is the common effector for cytokine secretion and pyroptosis downstream of inflammasome activation and was previously shown to form large transmembrane pores upon cleavage by inflammatory caspases to generate the GSDMD N-terminal domain (GSDMD-NT)1-10. Here we report that GSDMD Cys191 is S-palmitoylated and palmitoylation is required for pore formation.

Mar 21, 2024 | cgtlive.com | Judy Lieberman

This is the second part of an interview with Judy Lieberman, MD, PhD. For the first part, click here. “If you look at the PDR handbook, it's amazing for someone like me who graduated from medical school in 1981. The PDR now it's like mostly not conventional small molecules anymore.

Mar 1, 2024 | cgtlive.com | Judy Lieberman

“I was involved in [this] field from the beginning. I was the first person who showed you could use siRNAs in an animal model to treat disease and also to develop targeted RNA therapy where you could design RNAs that got into a specific cell type like a T-cell or a cancer cell and knock down one specific gene, for therapy.”Currently, there are 5 FDA-approved therapeutics based on small interfering RNA (siRNA), a type of RNA that can regulate expression of a specific gene.

Jan 9, 2024 | nature.com | Judy Lieberman

Cancer cells seed distant tissues and remain dormant before re-entering the cell cycle to form metastases. How tumor dormancy is maintained and how cells exit dormancy is poorly understood. A study shows that the lncRNA MALAT1 reactivates dormant cancer cells by upregulating serpin protease inhibitors in tumor cells to evade CD8+ T cells. Metastasis that can arise even decades after surgical resection of primary tumors is the leading cause of cancer-related death.

Jul 24, 2023 | pnas.org | Judy Lieberman |Damon Centola |Joshua Becker |Jingwen Zhang

Disulfiram blocks inflammatory TLR4 signaling by targeting MD-2Yang Bai, Rui Min, Pengcheng Chen, +9 , Shenglin Mei, Fan Deng, Zengzhang Zheng, Cong Jiang, Rui Miao, Zeyu Wu, Peng Zhang, Youdong Pan, Judy Lieberman https://orcid.org/0000-0002-6200-4715 [email protected], and Xing Liu https://orcid.org/0000-0002-6277-3856 [email protected] -9Authors Info & AffiliationsContributed by Judy Lieberman; received April 20, 2023; accepted June 23, 2023; reviewed by Katherine A.